3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
COVID-19
2
Severe Acute Respiratory Syndrome
1
Papillomavirus Infections
1
Multiple Myeloma
1
Mastocytosis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypersensitivity
1
Interventions
Cyclophosphamide
62
Rituximab
47
fludarabine
35
fludarabine phosphate
27
obinutuzumab
17
Mycophenolic Acid
16
ibrutinib
15
Whole-Body Irradiation
15
Lenalidomide
15
Specimen Handling
14
Prednisone
14
Etoposide
14
venetoclax
13
pirtobrutinib
13
Doxorubicin
13
pembrolizumab
12
Tacrolimus
12
Magnetic Resonance Spectroscopy
11
Granulocyte Colony-Stimulating Factor
11
Filgrastim
11
Biopsy
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
X-Rays
9
Bendamustine Hydrochloride
9
polatuzumab vedotin
8
glofitamab
8
acalabrutinib
8
Immunotherapy, Adoptive
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
2019-nCoV Vaccine mRNA-1273
×
1 year
×
Clear all
NCT05556720
2025-10-03
BOOST-IC
Monash University
Phase 3
Active not recruiting
960 enrolled